Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68, 394–424. https://doi.org/10.3322/caac.21492

Article  PubMed  Google Scholar 

Goodman, L. S., Wintrobe, M. M., Dameshek, W., Goodman, M. J., Gilman, A., & McLennan, M. T. (1946). Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA, 1984(251), 2255–2261. https://doi.org/10.1001/jama.251.17.2255

Article  Google Scholar 

DeVita, V. T, Lawrence, T., & Rosenberg, S.A. (2022). DeVita, Hellman, and Rosenberg’s cancer: Principles & practice of oncology. Part III: Cancer therapeutics (12th ed., pp. 218–386). WOLTERS KLUWER.

O’Leary, B., Finn, R. S., & Turner, N. C. (2016). Treating cancer with selective CDK4/6 inhibitors. Nature Reviews Clinical Oncology, 13, 417–430. https://doi.org/10.1038/nrclinonc.2016.26

Article  CAS  PubMed  Google Scholar 

Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E. (2020). PARP inhibitors: Clinical relevance, mechanisms of action and tumor resistance. Frontiers in Cell and Developmental Biology, 8, 564601. https://doi.org/10.3389/fcell.2020.564601

Article  PubMed  PubMed Central  Google Scholar 

Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J. (2016). Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine, 375, 1925–1936. https://doi.org/10.1056/NEJMoa1607303

Article  CAS  PubMed  Google Scholar 

Yardley, D. A. (2013). nab-Paclitaxel mechanisms of action and delivery. Journal of Controlled Release Official Journal of the Controlled Release, 170, 365–372. https://doi.org/10.1016/j.jconrel.2013.05.041

Article  CAS  Google Scholar 

Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020). Antibody–drug conjugates: A comprehensive review. Molecular Cancer Research, 18, 3–19. https://doi.org/10.1158/1541-7786.MCR-19-0582

Article  CAS  PubMed  Google Scholar 

Thomas, A., Teicher, B. A., & Hassan, R. (2016). Antibody–drug conjugates for cancer therapy. The Lancet Oncology, 17, e254–e262. https://doi.org/10.1016/S1470-2045(16)30030-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., & Overington, J. P. (2017). A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery, 16, 19–34. https://doi.org/10.1038/nrd.2016.230

Article  CAS  PubMed  Google Scholar 

Roskoski, R. (2020). Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacological Research, 152, 104609. https://doi.org/10.1016/j.phrs.2019.104609

Article  CAS  PubMed  Google Scholar 

Degirmenci, U., Wang, M., & Hu, J. (2020). Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells, 9, 198. https://doi.org/10.3390/cells9010198

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reichardt, P. (2018). The story of imatinib in GIST - A journey through the development of a targeted therapy. Oncology Research and Treatment, 41, 472–477. https://doi.org/10.1159/000487511

Article  CAS  PubMed  Google Scholar 

Fricker, L. D. (2020). Proteasome inhibitor drugs. Annual review of pharmacology and toxicology, 60, 457–476. https://doi.org/10.1146/annurev-pharmtox-010919-023603

Article  CAS  PubMed  Google Scholar 

Jordan, V. C. (2006). The science of selective estrogen receptor modulators: Concept to clinical practice. Clinical Cancer Research, 12, 5010–5013. https://doi.org/10.1158/1078-0432.CCR-06-1136

Article  CAS  PubMed  Google Scholar 

Patel, H. K., & Bihani, T. (2018). Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacology & Therapeutics, 186, 1–24. https://doi.org/10.1016/j.pharmthera.2017.12.012

Article  CAS  Google Scholar 

Hernando, C., Ortega-Morillo, B., Tapia, M., Moragón, S., Martínez, M. T., Eroles, P., Garrido-Cano, I., Adam-Artigues, A., Lluch, A., Bermejo, B., & Cejalvo, J. M. (2021). Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: Present and future from a clinical perspective. International Journal of Molecular Sciences, 22, 7812. https://doi.org/10.3390/ijms22157812

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang, Z. (2021). Regulation of cell cycle progression by growth factor-induced cell signaling. Cells, 10, 3327. https://doi.org/10.3390/cells10123327

Article  CAS  PubMed  PubMed Central  Google Scholar 

Du, Z., & Lovly, C. M. (2018). Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer, 17, 58. https://doi.org/10.1186/s12943-018-0782-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adams, G. P., & Weiner, L. M. (2005). Monoclonal antibody therapy of cancer. Nature Biotechnology, 23, 1147–1157. https://doi.org/10.1038/nbt1137

Article  CAS  PubMed  Google Scholar 

Sidéris, L., Dubé, P., & Rinke, A. (2012). Antitumor effects of somatostatin analogs in neuroendocrine tumors. The Oncologist, 17, 747–755. https://doi.org/10.1634/theoncologist.2011-0458

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mody, K., Baldeo, C., & Bekaii-Saab, T. (2018). Antiangiogenic therapy in colorectal cancer. The Cancer Journal Sudbury Mass, 24, 165–170. https://doi.org/10.1097/PPO.0000000000000328

Article  PubMed  Google Scholar 

Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018). Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. International Immunopharmacology, 62, 29–39. https://doi.org/10.1016/j.intimp.2018.06.001

Article  CAS  PubMed  Google Scholar 

Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12, 252–264. https://doi.org/10.1038/nrc3239

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Miguel, M., Umana, P., Gomes de Morais, A. L., Moreno, V., & Calvo, E. (2021). T-cell-engaging therapy for solid tumors. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 27, 1595–1603. https://doi.org/10.1158/1078-0432.CCR-20-2448

Article  PubMed  Google Scholar 

Goebeler, M. E., & Bargou, R. C. (2020). T cell-engaging therapies — BiTEs and beyond. Nature Reviews Clinical Oncology, 17(7), 418–434. https://doi.org/10.1038/s41571-020-0347-5

Article  PubMed  Google Scholar 

June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359, 1361–1365. https://doi.org/10.1126/science.aar6711

Article  CAS  PubMed  Google Scholar 

Slaney, C. Y., Wang, P., Darcy, P. K., & Kershaw, M. H. (2018). CARs versus BiTEs: A comparison between T cell–redirection strategies for cancer treatment. Cancer Discovery, 8, 924–934. https://doi.org/10.1158/2159-8290.CD-18-0297

Article  CAS  PubMed